Stocks CSBR Financial statements
Financial statementsCHAMPIONS ONCOLOGY, INC. financial statements
Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data CHAMPIONS ONCOLOGY, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.4 | 20.2 | 27.1 | 32.1 | 41 | 49.1 | 53.9 | 50.2 | 56.9 | 59.4 |
| Cost of revenue | 17 | 21.4 | 23.6 | 29.5 | 29.4 | 28.4 | 30.9 | |||
| Gross profit | 15.1 | 19.6 | 25.5 | 24.3 | 20.8 | 28.6 | 28.5 | |||
| Research and development | 4.29 | 4.4 | 4.8 | 5.85 | 7.2 | 9.37 | 11.5 | 9.54 | 6.83 | 9.08 |
| Selling and marketing | 3.26 | 2.57 | 3.06 | 4.24 | 5.52 | 6.38 | 7 | 7.06 | 7.55 | 9.32 |
| General and administrative | 4.96 | 4.07 | 4.68 | 6.61 | 6.51 | 9.12 | 10.2 | 11.1 | 9.34 | 11.2 |
| Operating expenses | 22.2 | 21.6 | 26.8 | 33.9 | ||||||
| Operating income | -6.81 | -1.35 | 0.27 | -1.92 | 0.37 | 0.61 | -5.26 | -7.36 | 4.55 | -1.14 |
| Other non-operating income | -0.06 | -0.09 | -0.04 | -0.04 | 0.07 | -0.02 | -0.01 | 0.05 | 0.07 | 0.21 |
| Pre-tax income | -6.87 | -1.44 | 0.23 | -1.96 | 0.44 | 0.58 | -5.27 | -7.31 | 4.63 | -0.93 |
| Income tax | 0.02 | 0.03 | 0.1 | 0.13 | 0.08 | 0.04 | 0.07 | -0.03 | -0.08 | 0.25 |
| Net income | -6.88 | -1.48 | 0.13 | -2.09 | 0.36 | 0.55 | -5.34 | -7.28 | 4.7 | -1.18 |
| EBITDA | -6.64 | -0.99 | 0.88 | -1.1 | 1.29 | 2.11 | -3.16 | -5.46 | 6.15 | 0.26 |
| EPS, basic | -0.68 | -0.14 | 0.01 | -0.18 | 0.03 | 0.04 | -0.39 | -0.54 | 0.34 | -0.08 |
| EPS, diluted | -0.68 | -0.14 | 0.01 | -0.18 | 0.02 | 0.04 | -0.39 | -0.54 | 0.33 | -0.08 |
| Shares, basic (weighted) | 10.1 | 10.4 | 10.7 | 11.8 | 13.1 | 13.2 | 13.5 | 13.5 | 13.7 | 13.8 |
| Shares, diluted (weighted) | 10.1 | 10.4 | 13.3 | 11.8 | 14.6 | 14.2 | 13.5 | 13.5 | 14.3 | 13.8 |
Balance sheet
| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.3 | 0.86 | 3.24 | 8.34 | 4.69 | 9.01 | 10.1 | 2.62 | 9.79 | 4.87 |
| Receivables | 2.27 | 3.92 | 4.38 | 4.77 | 6.99 | 9.51 | 8.01 | 9.53 | 11.2 | 13.2 |
| Other current assets | 0.3 | 0.29 | 0.31 | 0.39 | 0.96 | 1.14 | 1.33 | 1.5 | 1.37 | 1.17 |
| Total current assets | 5.87 | 5.06 | 7.92 | 13.5 | 12.6 | 19.7 | 19.5 | 13.6 | 22.4 | 19.2 |
| Property, plant and equipment | 1.22 | 2.08 | 2.55 | 3.99 | 6.09 | 7.13 | 7.19 | 5.72 | 4.38 | 3.53 |
| Lease right-of-use assets | 0 | 2.8 | 8.52 | 8.23 | 7.32 | 6.25 | 5.08 | 3.7 | ||
| Goodwill | 0.67 | 0.67 | 0.67 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 |
| Other non-current assets | 0.11 | 0.12 | 0.13 | 0.13 | 0.02 | 0.02 | 0.02 | 0.19 | 0.2 | 0.21 |
| Total assets | 8.01 | 8.08 | 11.3 | 20.8 | 27.6 | 35.4 | 34.3 | 26.1 | 32.3 | 27 |
| Accounts payable | 1.85 | 2.15 | 2.81 | 3.14 | 1.89 | 2.87 | 5.33 | 5.8 | 4.25 | 6.9 |
| Accrued liabilities | 0.69 | 0.57 | 1.18 | 2.72 | 2.23 | 2.41 | 2.27 | 2.16 | 2.56 | 2.59 |
| Deferred revenue | 4.91 | 4.7 | 4.02 | 5.8 | 6.26 | 11.1 | 12.8 | 12.1 | 15.4 | 8.83 |
| Total current liabilities | 7.45 | 7.45 | 8.03 | 12.3 | 11.2 | 17.5 | 21.7 | 21.5 | 23.9 | 19.9 |
| Lease liabilities | 0 | 3.17 | 8.78 | 8.41 | 7.39 | 6.09 | 4.63 | 2.99 | ||
| Other non-current liabilities | 0.16 | 0.15 | 0.15 | 0.18 | 0.18 | 0.39 | 0.55 | 0.4 | 0.09 | 0.01 |
| Total liabilities | 7.61 | 8.08 | 9.03 | 15.7 | 20.2 | 26.3 | 29.7 | 28 | 28.6 | 22.9 |
| Paid-in capital | 71 | 72.1 | 72.9 | 78 | 79.9 | 81.1 | 82 | 83.4 | 84.4 | 85.7 |
| Retained earnings | -69.4 | -70.8 | -70.7 | -72.9 | -72.5 | -72 | -77.3 | -84.6 | -79.9 | -81.1 |
| Treasury stock | -1.25 | -1.25 | 0 | 0 | -0.07 | -0.71 | -0.71 | -0.71 | ||
| Shareholders' equity | 0.4 | 0 | 2.14 | 5.1 | 7.43 | 9.1 | 4.64 | -1.9 | 3.77 | 3.94 |
| Minority interests | 0 | 0.13 | ||||||||
| Total equity | 0.4 | 0 | 2.14 | 5.1 | 7.43 | 9.1 | 4.64 | -1.9 | 3.77 | 4.07 |
| Total liabilities and equity | 8.01 | 8.08 | 11.3 | 20.8 | 27.6 | 35.4 | 34.3 | 26.1 | 32.3 | 27 |
| Shares outstanding | 10.4 | 10.4 | 11 | 12.7 | 13.4 | 13.5 | 13.5 | 13.6 | 13.8 | 13.9 |
Cash flow statement
| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income | -6.88 | -1.48 | 0.13 | -2.09 | 0.36 | 0.55 | -5.34 | -7.28 | 4.7 | -1.18 |
| Depreciation and amortization | 0.17 | 0.36 | 0.61 | 0.83 | 0.93 | 1.5 | 2.1 | 1.9 | 1.6 | 1.4 |
| Stock-based compensation | 2.66 | 1 | 0.64 | 0.6 | 0.6 | 0.91 | 0.86 | 1.12 | 0.65 | 1.24 |
| Deferred income tax | 0 | 0 | ||||||||
| Change in receivables | -0.99 | -1.6 | -0.53 | -0.67 | -2.27 | -2.82 | 1.31 | -1.99 | -1.44 | -2 |
| Change in payables | -0.04 | 0.3 | 0.65 | 0.33 | -1.25 | 0.97 | 2.47 | 0.47 | -1.75 | 2.56 |
| Cash from operations | -2.84 | -1.23 | 1.86 | 2.91 | -1.68 | 6.5 | 3.97 | -6.14 | 7.39 | -4.47 |
| Capital expenditures | -0.77 | -1.23 | -0.83 | -2.22 | -3.28 | -2.38 | -2.87 | -0.84 | -0.39 | -0.56 |
| Cash from investing | -0.77 | -1.23 | -0.83 | -2.22 | -3.17 | -2.38 | -2.87 | -0.84 | -0.39 | -0.54 |
| Stock issued | 4.34 | 0 | 0.21 | 0.09 | 0.25 | 0.32 | 0.23 | |||
| Share buybacks | 0 | -0.07 | -0.63 | 0 | ||||||
| Cash from financing | 4.32 | 0.01 | 1.2 | 4.42 | 1.2 | 0.21 | 0.01 | -0.53 | 0.17 | 0.1 |
| Net change in cash | 0.71 | -2.44 | 2.23 | 5.11 | -3.66 | 4.32 | 1.11 | -7.5 | 7.17 | -4.91 |
| Free cash flow | -3.61 | -2.46 | 1.03 | 0.69 | -4.96 | 4.11 | 1.1 | -6.97 | 7 | -5.04 |
| Income taxes paid | 0.04 | 0.24 |
Key metrics
Profitability
| Metric | Value | How it is calculated |
|---|---|---|
| Gross margin | 49.8% | Gross profit / revenue. |
| Operating margin | -1.7% | Operating income / revenue. |
| EBITDA margin | 0.5% | EBITDA (operating income + depreciation and amortization) / revenue. |
| Pre-tax margin | -1.5% | Pre-tax income / revenue. |
| Net margin | -1.9% | Net income / revenue. |
| FCF margin | -10.1% | Free cash flow (cash from operations - capital expenditures) / revenue. |
| Operating cash flow margin | -9.2% | Cash from operations / revenue. |
| Return on equity (ROE) | -29.2% | Net income / average shareholders' equity (opening and closing). Not shown when equity is negative. |
| Return on assets (ROA) | -3.4% | Net income / average total assets. |
| R&D / revenue | 15.4% | Research and development expense / revenue. |
| Stock-based pay / revenue | 3.0% | Stock-based compensation (from the cash flow statement) / revenue. |
| Capex / revenue | 0.9% | Capital expenditures / revenue. |
| D&A / revenue | 2.2% | Depreciation and amortization / revenue. |
Growth
| Metric | Value | How it is calculated |
|---|---|---|
| Revenue growth, 1y | 4.4% | Revenue vs the same period a year earlier. Only from a positive base. |
| Revenue CAGR, 3y | 3.3% | Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Revenue CAGR, 5y | 7.7% | Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Gross profit growth, 1y | -0.1% | Gross profit vs the same period a year earlier. Only from a positive base. |
| Gross profit CAGR, 3y | 5.4% | Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Gross profit CAGR, 5y | 7.8% | Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Operating income growth, 1y | -125.0% | Operating income vs the same period a year earlier. Only from a positive base. |
| EBITDA growth, 1y | -95.8% | EBITDA vs the same period a year earlier. Only from a positive base. |
| EBITDA CAGR, 5y | -27.4% | Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Net income growth, 1y | -125.0% | Net income vs the same period a year earlier. Only from a positive base. |
| EPS growth, 1y | -124.2% | EPS vs the same period a year earlier. Only from a positive base. |
| Operating cash flow growth, 1y | -160.5% | Operating cash flow vs the same period a year earlier. Only from a positive base. |
| Free cash flow growth, 1y | -172.0% | Free cash flow vs the same period a year earlier. Only from a positive base. |
| Book value growth, 1y | 4.4% | Book value vs the same period a year earlier. Only from a positive base. |
| Book value CAGR, 3y | -5.3% | Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Book value CAGR, 5y | -11.9% | Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Total assets growth, 1y | -16.6% | Total assets vs the same period a year earlier. Only from a positive base. |
| Total assets CAGR, 3y | -7.7% | Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive. |
| Total assets CAGR, 5y | -0.4% | Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive. |
| Share count change, 1y | -3.0% | Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution. |
| Share count change per year, 3y | 0.7% | Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution. |
| Share count change per year, 5y | -1.0% | Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution. |
Balance sheet health
| Metric | Value | How it is calculated |
|---|---|---|
| Current ratio | 1.03x | Current assets / current liabilities. |
| Quick ratio | 0.96x | (Cash + short-term investments + receivables) / current liabilities. |
| Cash ratio | 0.23x | (Cash + short-term investments) / current liabilities. |
| Liabilities / assets | 86.6% | Total liabilities / total assets. |
| Working capital | $563.0K | Current assets - current liabilities. |
| Goodwill and intangibles / assets | 1.0% | (Goodwill + intangible assets) / total assets. |
| Tangible book value | $3.6M | Shareholders' equity - goodwill - intangible assets. |
Efficiency
| Metric | Value | How it is calculated |
|---|---|---|
| Asset turnover | 1.82x | Revenue / average total assets. |
| Fixed asset turnover | 16.0x | Revenue / average property, plant and equipment. |
| Receivables turnover | 4.46x | Revenue / average receivables. |
| Days sales outstanding | 82 days | 365 x average receivables / revenue. |
| Days payables | 68 days | 365 x average accounts payable / cost of revenue. |
Per share
| Metric | Value | How it is calculated |
|---|---|---|
| EPS, diluted | -$0.08 | Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS. |
| Revenue per share | $4.36 | Revenue / diluted weighted shares. |
| FCF per share | -$0.44 | Free cash flow / diluted weighted shares. |
| Operating cash flow per share | -$0.40 | Cash from operations / diluted weighted shares. |
| Book value per share | $0.28 | Shareholders' equity / shares outstanding (diluted weighted shares when not reported). |
| Tangible book per share | $0.26 | Tangible book value / shares outstanding. |
| Cash per share | $0.31 | (Cash + short-term investments) / shares outstanding. |
Valuation
| Metric | Value | How it is calculated |
|---|---|---|
| Market cap | $68.1M | Share price x shares outstanding. |
| Enterprise value | $63.7M | Market cap + total debt - cash - short-term investments. |
| P/S | 1.12x | Market cap / revenue. |
| P/B | 17.5x | Market cap / shareholders' equity. Only when equity is positive. |
| Price / tangible book | 19.1x | Market cap / tangible book value, when positive. |
| EV/Sales | 1.05x | Enterprise value / revenue. |
| EV/EBITDA | 220x | Enterprise value / EBITDA, when both are positive. |
| FCF yield | -9.0% | Free cash flow / market cap. |
| Earnings yield | -1.7% | Net income / market cap (the inverse of P/E). |
What was CHAMPIONS ONCOLOGY, INC.'s revenue in fiscal 2026?
CHAMPIONS ONCOLOGY, INC. reported revenue of $59.4M for fiscal 2026, 4.4% higher than the year before.
Was CHAMPIONS ONCOLOGY, INC. profitable in fiscal 2026?
No. It reported a net loss of $1.2M.
How much free cash flow did CHAMPIONS ONCOLOGY, INC. generate in fiscal 2026?
Cash from operations of $4.5M minus capital expenditures of $564.0K left free cash flow of -$5.0M.